Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Apr 18, 2024 6:26pm
97 Views
Post# 35996969

RE:New shareholder

RE:New shareholderWelcome. And further to your comments, the 2024 Canadian Federal budget unveiled Tuesday, had the federal government increasing the inclusion rate of the capital gains tax from 50 per cent to 67 per cent for businesses and trusts. 

The proposed change, if adopted, would come into effect on June 25, 2024 and would be a date that any Canadian company looking to acquired would want to have the announcement to have happen before that date.

Should an acquisition announcement be made before June 25, 2024, a 50% capital gain tax would be grandfathered-in ... even though the final closure date may be one that would sometime after the June 25, 2024.

Otherwise, ONCY and its Canadian shareholders would become subject to a 67% capital gains tax on the acquisition of ONCY.
<< Previous
Bullboard Posts
Next >>